MCID: TXP001
MIFTS: 65

Toxoplasmosis

Categories: Blood diseases, Fetal diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxoplasmosis

MalaCards integrated aliases for Toxoplasmosis:

Name: Toxoplasmosis 12 76 55 43 3 44 15 73
Multisystemic Disseminated Toxoplasmosis 73
Disseminated Toxoplasmosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9965
ICD10 33 B58 B58.9 B58.8
ICD9CM 35 130 130.9
MeSH 44 D014123
NCIt 50 C3418
SNOMED-CT 68 9399000

Summaries for Toxoplasmosis

MedlinePlus : 43 Toxoplasmosis is a disease caused by the parasite Toxoplasma gondii. More than 60 million people in the U.S. have the parasite. Most of them don't get sick. But the parasite causes serious problems for some people. These include people with weak immune systems and babies whose mothers become infected for the first time during pregnancy. Problems can include damage to the brain, eyes, and other organs. You can get toxoplasmosis from Waste from an infected cat Eating contaminated meat that is raw or not well cooked Using utensils or cutting boards after they've had contact with contaminated raw meat Drinking infected water Receiving an infected organ transplant or blood transfusion Most people with toxoplasmosis don't need treatment. There are drugs to treat it for pregnant women and people with weak immune systems. Centers for Disease Control and Prevention

MalaCards based summary : Toxoplasmosis, also known as multisystemic disseminated toxoplasmosis, is related to congenital toxoplasmosis and ocular toxoplasmosis, and has symptoms including fever and pruritus. An important gene associated with Toxoplasmosis is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs leucovorin and Sulfadiazine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and brain, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A coccidiosis that has material basis in protozoan Toxoplasma gondii. The parasite effects most genera of warm-blooded animals, including humans, but the primary host is the felid (cat) family. Animals are infected by eating infected meat, by ingestion of feces of a cat that has itself recently been infected, or transmission_by mother to fetus. The symptoms include bilateral, nontender cervical or axillary lymphadenopathy, fever, malaise, myalgia, hepatosplenomegaly, anemia and leukopenia.

CDC : 3 However, women newly infected with Toxoplasma during or shortly before pregnancy and anyone with a compromised immune system should be aware that toxoplasmosis can have severe consequences.

Wikipedia : 76 Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii. Infections with toxoplasmosis usually... more...

Related Diseases for Toxoplasmosis

Diseases in the Toxoplasmosis family:

Congenital Toxoplasmosis

Diseases related to Toxoplasmosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 536)
# Related Disease Score Top Affiliating Genes
1 congenital toxoplasmosis 34.0 CD40LG CD79A HLA-DQA1 HLA-DQB1 TLR9
2 ocular toxoplasmosis 33.8 CCR5 CD40LG CD79A TLR9
3 pneumocystosis 30.5 CD40LG DHFR TNF
4 uveitis 30.2 IFNG IL10 IL4 TNF
5 rubella 30.2 CD40LG HLA-DQB1 IL10 IL4 TNF
6 acquired immunodeficiency syndrome 30.2 CCR5 IFNG IL10 IL1B IL6 TNF
7 cytomegalovirus infection 30.1 IL1B IL6 TNF
8 cryptosporidiosis 30.1 CD40LG CD79A DHFR
9 hematopoietic stem cell transplantation 30.1 IFNG IL10 IL6 TNF
10 congenital cytomegalovirus 30.0 IL1B TLR2 TNF
11 post-transplant lymphoproliferative disease 29.8 IL10 IL6 TNF
12 schistosomiasis 29.8 CD40LG IFNG IL10 IL4 TNF
13 scleritis 29.8 IFNG IL4 TNF
14 campylobacteriosis 29.7 IFNG IL1B TLR4
15 cryptococcosis 29.7 IFNG IL4 TLR9
16 lymphadenitis 29.7 IFNG IL10 IL1B TLR4 TNF
17 arthritis 29.7 HLA-DQB1 IFNG IL10 IL1B IL6 TNF
18 myasthenia gravis 29.6 IFNG IL10 IL4 TNF
19 posterior uveitis 29.6 IFNG IL6 TNF
20 brucellosis 29.6 CD40LG IFNG IL10 IL4 IL6 TLR4
21 chikungunya 29.6 IL1B IL6 TNF
22 extrinsic allergic alveolitis 29.6 IL10 IL1B IL6
23 adult respiratory distress syndrome 29.6 IL10 IL6 TNF
24 acute respiratory distress syndrome 29.6 IL1B IL6 TNF
25 human immunodeficiency virus infectious disease 29.6 CCR5 IFNG IL10 IL6 TLR9 TNF
26 leptospirosis 29.5 IFNG IL10 IL1B IL6 TLR2 TNF
27 cysticercosis 29.5 IL1B IL6 TLR4
28 acute disseminated encephalomyelitis 29.5 HLA-DQA1 HLA-DQB1 IL10 IL1B
29 immunodeficiency with hyper-igm, type 1 29.5 CD40 CD40LG CD79A IL4
30 aplastic anemia 29.5 IFNG IL4 IL6 TNF
31 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.5 CCR5 CD40LG IFNG IL10 IL4
32 diabetes mellitus 29.4 CCR5 HLA-DQA1 HLA-DQB1 IFNG IL1B IL6
33 neuritis 29.4 IFNG IL1B IL4 TNF
34 kawasaki disease 29.4 IL10 IL6 MYD88 TNF
35 meningoencephalitis 29.4 CD40LG CD79A IL6 TLR9
36 peritonitis 29.3 IL10 IL1B IL6 TLR2 TNF
37 echinococcosis 29.3 IFNG IL10 IL6 TLR2 TLR4 TNF
38 meningitis 29.3 IFNG IL10 IL1B IL6 TLR2 TLR9
39 typhoid fever 29.2 IFNG IL1B IL6 TLR4 TNF
40 viral hepatitis 29.2 HLA-DQA1 TLR2 TLR9 TNF
41 lyme disease 29.2 CD40LG IL1B IL6 TLR2 TNF
42 graft-versus-host disease 29.1 HLA-DQB1 IFNG IL10 IL1B IL6 TNF
43 coccidiosis 29.1 IFNG IL10 IL4 RHD TLR9 TNF
44 pneumonia 29.1 CD40LG IL10 IL1B IL6 TLR2 TLR4
45 central nervous system vasculitis 29.0 IFNG IL1B IL6 TLR9 TNF
46 trypanosomiasis 29.0 IFNG IL10 IL1B IL4 IL6 TLR2
47 tonsillitis 28.9 CD79A IFNG IL1B IL4 IL6 TLR9
48 viral infectious disease 28.9 CCR5 CD40LG IFNG IL10 IL1B IL4
49 pulmonary tuberculosis 28.9 IFNG IL10 IL4 TLR2 TLR9 TNF
50 nervous system disease 28.8 IFNG IL10 IL1B IL6 TLR9 TNF

Graphical network of the top 20 diseases related to Toxoplasmosis:



Diseases related to Toxoplasmosis

Symptoms & Phenotypes for Toxoplasmosis

UMLS symptoms related to Toxoplasmosis:


fever, pruritus

GenomeRNAi Phenotypes related to Toxoplasmosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 CD40LG DHFR HLA-DQB1 IL10 IL1B MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 CD40LG DHFR HLA-DQB1 IL10 IL1B MYD88

MGI Mouse Phenotypes related to Toxoplasmosis:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.55 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
2 homeostasis/metabolism MP:0005376 10.51 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
3 immune system MP:0005387 10.5 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
4 cellular MP:0005384 10.46 CCR5 CD40LG CD79A DHFR HLA-DQB1 IFNG
5 cardiovascular system MP:0005385 10.4 CCR5 CD40LG DHFR HLA-DQB1 IFNG IL10
6 digestive/alimentary MP:0005381 10.35 CCR5 HLA-DQB1 IFNG IL10 IL4 IL6
7 endocrine/exocrine gland MP:0005379 10.35 CD40 CD40LG HLA-DQA1 HLA-DQB1 IFNG IL10
8 mortality/aging MP:0010768 10.35 CCR5 CD40LG DHFR HLA-DQB1 IFNG IL10
9 growth/size/body region MP:0005378 10.34 DHFR HLA-DQB1 IFNG IL10 IL1B IL4
10 integument MP:0010771 10.29 ALOX12 CD40LG DHFR IFNG IL10 IL1B
11 nervous system MP:0003631 10.28 CCR5 CD40 CD40LG CD79A HLA-DQB1 IFNG
12 liver/biliary system MP:0005370 10.27 CCR5 CD79A DHFR HLA-DQB1 IFNG IL10
13 muscle MP:0005369 10.16 CCR5 DHFR HLA-DQB1 IFNG IL10 IL6
14 neoplasm MP:0002006 10.13 CCR5 CD79A IFNG IL10 IL1B IL6
15 renal/urinary system MP:0005367 10.1 CD40 CD40LG CD79A HLA-DQB1 IFNG IL4
16 reproductive system MP:0005389 10 CCR5 CD40LG HLA-DQB1 IFNG IL10 IL4
17 no phenotypic analysis MP:0003012 9.91 CCR5 CD79A IFNG IL10 IL4 MYD88
18 respiratory system MP:0005388 9.81 HLA-DQB1 IFNG IL10 IL4 IL6 MYD88
19 skeleton MP:0005390 9.73 CD40 CD40LG IFNG IL10 IL1B IL4
20 vision/eye MP:0005391 9.28 CCR5 IFNG IL10 IL4 IL6 MYD88

Drugs & Therapeutics for Toxoplasmosis

Drugs for Toxoplasmosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
2
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 68-35-9 5215
3
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-14-0 4993
4
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
5
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
6
Sulfamethoxazole Approved Phase 4,Phase 3 723-46-6 5329
7
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1 155213-67-5 392622
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Nevirapine Approved Phase 4 129618-40-2 4463
10
Spiramycin Approved Phase 4,Phase 3 24916-50-5
11
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
13
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1
23
protease inhibitors Phase 4,Phase 3,Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Psychotropic Drugs Phase 4
27 Central Nervous System Depressants Phase 4
28 Neurotransmitter Agents Phase 4
29 GABA Agents Phase 4
30 Anticonvulsants Phase 4
31 Tranquilizing Agents Phase 4
32 Antimanic Agents Phase 4
33 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4,Phase 3
34 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 1
36 Anti-HIV Agents Phase 4,Phase 3,Phase 1
37 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 1
38 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39 Atazanavir Sulfate Phase 4,Phase 3,Phase 1
40 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 1
41 Anti-Retroviral Agents Phase 4,Phase 3,Phase 1
42 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
43 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
44 Micronutrients Phase 4,Phase 3,Phase 1
45 Vitamins Phase 4,Phase 3,Phase 1
46 Trace Elements Phase 4,Phase 3,Phase 1
47 Antidotes Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Bone Density Conservation Agents Phase 4,Phase 1
49 Calcium, Dietary Phase 4,Phase 2,Phase 1,Not Applicable
50
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia Completed NCT02011750 Phase 4 Sodium Valproate treatment;Placebo
2 Treatment of Cerebral Toxoplasmosis in HIV/AIDS Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
3 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
4 Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis Recruiting NCT00004317 Phase 4 Leucovorin calcium;Pyrimethamine;Spiramycin;Sulfadiazine
5 Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis Unknown status NCT01202500 Phase 3
6 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
7 Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy Completed NCT01189448 Phase 3 Pyrimethamine/Sulfadiazine;Spiramycine
8 Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis Completed NCT01449877 Phase 3 Trimethoprim-Sulfamethoxazole
9 Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression Completed NCT00300404 Phase 3 daraprim;pyrimethamine;folinic acid
10 A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients Completed NCT00000991 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Dapsone;Zidovudine
11 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
12 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
13 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
14 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
15 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
16 Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients Completed NCT00000643 Phase 2 Pyrimethamine;Leucovorin calcium
17 Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis Completed NCT00000794 Phase 2 Sulfadiazine;Clarithromycin;Atovaquone;Pyrimethamine;Leucovorin calcium
18 A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease Completed NCT01470599 Phase 2 CP-690,550;CP-690,550
19 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals Completed NCT00885703 Phase 1, Phase 2 Fluconazole;Amphotericin B
20 Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant Completed NCT02668315 Phase 1, Phase 2
21 A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia Active, not recruiting NCT02008773 Phase 2 Valacyclovir HCI 500 mg tablets;placebo
22 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
23 Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects Completed NCT03258762 Phase 1 Pyrimethamine;Calcium folinate
24 A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients Completed NCT00000973 Phase 1 Pyrimethamine;Leucovorin calcium;Zidovudine
25 Antiretroviral Drug Interaction Study in Volunteers With HIV Completed NCT01479361 Phase 1 Atovaquone 750 mg twice daily;Atovaquone 1500 mg twice daily
26 A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS Completed NCT00000966 Phase 1 Azithromycin;Pyrimethamine;Leucovorin calcium
27 A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC Completed NCT00000680 Phase 1 Zidovudine;Aldesleukin
28 A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis Withdrawn NCT00679744 Phase 1 Pyrimethamine
29 Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis Completed NCT02843438 Not Applicable Anti-toxoplasmosis treatment;Anti-inflammatory treatments
30 Cerebral Toxoplasmosis and AIDS Completed NCT00803621
31 A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection Completed NCT00000666 Not Applicable Pyrimethamine
32 A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine Completed NCT00001994 Not Applicable Atovaquone
33 A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS Completed NCT00000674 Not Applicable Pyrimethamine;Leucovorin calcium;Clindamycin
34 Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse Completed NCT00002064 Not Applicable Pyrimethamine;Clindamycin
35 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Completed NCT00645697
36 Drug Exposure Registry for GSK2248761, an Investigational NNRTI Completed NCT01458132 Not Applicable GSK2248761
37 Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma Completed NCT00226304
38 Expanded Noninvasive Genomic Medical Assessment: The Enigma Study Completed NCT02787486
39 HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University Completed NCT01339416
40 Uveitis Gene-Expression Profiling Completed NCT00874471
41 Kaiser Permanente HIV Cohort Study Completed NCT01339403
42 New Diagnostic Approach for Congenital Toxoplasmosis Recruiting NCT03385499 Not Applicable
43 Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis Recruiting NCT02863588 Not Applicable
44 Lyon Cohort of Maternal and Congenital Toxoplasma Infections Recruiting NCT02936921
45 Apheresis of Patients With Immunodeficiency Recruiting NCT01212055
46 Genetics of Uveitis Recruiting NCT02357238
47 Intestinal Parasites in Inhabitants of Kuyavian-Pomeranian Province in Poland Recruiting NCT03490435
48 Clinical Studies of Kikuchi's Disease Withdrawn NCT00172445 Not Applicable

Search NIH Clinical Center for Toxoplasmosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: toxoplasmosis

Genetic Tests for Toxoplasmosis

Anatomical Context for Toxoplasmosis

MalaCards organs/tissues related to Toxoplasmosis:

41
Eye, Testes, Brain, Lymph Node, T Cells, Heart, B Cells

Publications for Toxoplasmosis

Articles related to Toxoplasmosis:

(show top 50) (show all 2270)
# Title Authors Year
1
Toxoplasmosis and secondary Guillain-Barré associated with ruxolitinib as graft-versus-host disease treatment. ( 30207078 )
2019
2
Congenital human toxoplasmosis caused by non-clonal Toxoplasma gondii genotypes in Argentina. ( 30304711 )
2019
3
Outbreak of toxoplasmosis in four squirrel monkeys (Saimiri sciureus) in Japan. ( 30347233 )
2019
4
Serological diagnosis of Toxoplasmosis disease using a fluorescent immunosensor with chitosan-ZnO-nanoparticles. ( 30393087 )
2019
5
Live-attenuated Pru:I9cdpk2 strain of Toxoplasma gondii protects against acute, chronic and congenital toxoplasmosis. ( 29669003 )
2018
6
A novel chemiluminescent immunoassay based on original acridinium ester labels as better solution for diagnosis of human toxoplasmosis than conventional ELISA test. ( 29398460 )
2018
7
Toxoplasmosis submandibular lymphadenitis: Report of an unusual case with a brief review. ( 29731568 )
2018
8
Disseminated toxoplasmosis in a patient with advanced acquired immunodeficiency syndrome. ( 29588907 )
2018
9
Ocular toxoplasmosis: adverse reactions to treatment in a Brazilian cohort. ( 29788193 )
2018
10
Pediatric Amazonian Toxoplasmosis Caused by Atypical Strains in French Guiana, 2002-2017. ( 29957729 )
2018
11
Toxoplasmosis update. ( 29923924 )
2018
12
Cerebral toxoplasmosis with fever and erythematous macular rash: An initial presentation in an advanced HIV infection. ( 29930906 )
2018
13
Can offspring sex ratios help to explain the endocrine effects of toxoplasmosis infection on human behaviour? ( 29886408 )
2018
14
Decline of Seroprevalence and Incidence of Congenital Toxoplasmosis Despite Changing Prevention Policy - Three Decades of Cord-Blood Screening in North-Western Switzerland. ( 29561516 )
2018
15
Study of brainstem auditory evoked potentials in early diagnosis of congenital toxoplasmosis. ( 29929810 )
2018
16
Toxoplasmosis seroprevalence in rheumatoid arthritis patients: A systematic review and meta-analysis. ( 29870527 )
2018
17
Prenatal therapy with pyrimethamine + sulfadiazine versus spiramycin to reduce placental transmission of toxoplasmosis : A multicenter, randomized trial. ( 29870736 )
2018
18
Immune Protection of Rhoptry Protein 21 (ROP21) of <i>Toxoplasma gondii</i> as a DNA Vaccine Against Toxoplasmosis. ( 29867820 )
2018
19
Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and Chronic <i>Toxoplasmosis</i>. ( 29876322 )
2018
20
Increased IL-27/IL-27R expression in association with the immunopathology of murine ocular toxoplasmosis. ( 29779048 )
2018
21
Polymerase chain reaction (PCR) in ocular and ganglionar toxoplasmosis and the effect of therapeutics for prevention of ocular involvement in South American setting. ( 29409823 )
2018
22
Toxoplasmosis in the non-orthotopic heart transplant recipient population, how common is it? Any indication for prophylaxis? ( 29878911 )
2018
23
GENETIC POLYMORPHISMS IN CYTOKINE GENES IN COLOMBIAN PATIENTS WITH OCULAR TOXOPLASMOSIS. ( 29426041 )
2018
24
Hepatic Metabolomics Investigation in Acute and Chronic Murine Toxoplasmosis. ( 29922602 )
2018
25
CCR5 chemokine receptor gene polymorphisms in ocular toxoplasmosis. ( 29221851 )
2018
26
Author Response: Congenital Toxoplasmosis, Cytomegalovirus, and Zika Virus Infections: Emphasis on the Role of Neuroimaging in Screening, Prognostication, and Follow-Up. ( 29037966 )
2018
27
Early diagnosis and successful treatment of acquired toxoplasmosis infectious retinochoroiditis: A case report. ( 29952985 )
2018
28
MACULAR HOLE ASSOCIATED WITH TOXOPLASMOSIS: A SURGICAL CASE SERIES. ( 29975259 )
2018
29
Fatal toxoplasmosis in a southern muriqui (Brachyteles arachnoides) from SALo Paulo state, Brazil: Pathological, immunohistochemical, and molecular characterization. ( 29193137 )
2018
30
High heterogeneity, mixed infections and new genotypes in human congenital toxoplasmosis cases in the mega-metropolis of Central Mexico. ( 29170005 )
2018
31
Investigation of tissue cysts in the retina in a mouse model of ocular toxoplasmosis: distribution and interaction with glial cells. ( 29858945 )
2018
32
Patterns of ocular toxoplasmosis presenting at a tertiary eye care center in Korean patients. ( 29642204 )
2018
33
Congenital Toxoplasmosis, Cytomegalovirus, and Zika Virus Infections. ( 29037967 )
2018
34
Use of polymerase chain reaction (PCR) in the diagnosis of congenital toxoplasmosis. ( 29604343 )
2018
35
Assessment of ocular toxoplasmosis patients reported at a tertiary center in the northeast of Iran. ( 29335806 )
2018
36
Evaluation of Immune Responses Induced by<i>GRA7</i>and<i>ROP2</i>Genes by DNA Vaccine Cocktails Against Acute Toxoplasmosis in BALB/c Mice. ( 29296260 )
2018
37
Serologic Tests of IgG and IgM Antibodies and IgG Avidity for Diagnosis of Ocular Toxoplasmosis. ( 29742869 )
2018
38
Wnt-Spectrum Vitreoretinopathy Masquerading as Congenital Toxoplasmosis. ( 29927473 )
2018
39
Specialty management differences of syphilis and toxoplasmosis surrounding pregnancy: a prospective cross-sectional study. ( 29971681 )
2018
40
Current treatment of ocular toxoplasmosis in immunocompetent patients: a network meta-analysis. ( 29704469 )
2018
41
Correction to: Assessment of ocular toxoplasmosis patients reported at a tertiary center in the northeast of Iran. ( 29858749 )
2018
42
Diagnostic Value of Positive Findings of Toxoplasma gondii-Specific Immunoglobulin M Serum Antibody in Uveitis Patients to Confirm Ocular Toxoplasmosis. ( 29513626 )
2018
43
The potential risk of toxoplasmosis for traffic accidents: A systematic review and meta-analysis. ( 29906469 )
2018
44
Regional Differences in the Clinical Manifestation of Ocular Toxoplasmosis between the Center and Northeast of Argentina. ( 29953310 )
2018
45
Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis. ( 29452213 )
2018
46
Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice. ( 29309783 )
2018
47
Macrophage Migration Inhibitory Factor (MIF) Prevents Maternal Death, but Contributes to Poor Fetal Outcome During Congenital Toxoplasmosis. ( 29867817 )
2018
48
Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia. ( 29428267 )
2018
49
Congenital Toxoplasmosis: A Plea for a Neglected Disease. ( 29473896 )
2018
50
Cerebral Toxoplasmosis Diagnosed by Nested-Polymerase Chain Reaction in a Patient with Rheumatoid Arthritis. ( 29321415 )
2018

Variations for Toxoplasmosis

Expression for Toxoplasmosis

Search GEO for disease gene expression data for Toxoplasmosis.

Pathways for Toxoplasmosis

Pathways related to Toxoplasmosis according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 CCR5 CD40 CD40LG CD79A HLA-DQA1 HLA-DQB1
2
Show member pathways
13.78 CCR5 CD40 CD40LG IFNG IL10 IL1B
3
Show member pathways
13.58 CCR5 CD40 CD40LG IL10 IL1B IL4
4
Show member pathways
13.57 CD40 CD40LG CD79A HLA-DQA1 HLA-DQB1 MYD88
5
Show member pathways
13.5 CCR5 CD40 CD40LG HLA-DQA1 HLA-DQB1 IFNG
6
Show member pathways
13.41 CCR5 CD40 CD40LG IL10 IL1B IL4
7
Show member pathways
13.33 CD40 CD79A HLA-DQA1 HLA-DQB1 IFNG IL1B
8
Show member pathways
13.21 CCR5 IL1B IL6 MYD88 TLR2 TLR4
9
Show member pathways
13.19 CD40 IFNG IL10 IL1B IL6 MYD88
10
Show member pathways
13.08 CD40 CD40LG HLA-DQA1 HLA-DQB1 IFNG IL10
11
Show member pathways
12.93 IFNG IL1B IL6 MYD88 TLR4 TNF
12
Show member pathways
12.89 CD40 CD40LG IL1B IL6 MYD88 TLR2
13
Show member pathways
12.85 CCR5 CD40 CD40LG IFNG IL1B TNF
14
Show member pathways
12.84 CD40 CD40LG CD79A HLA-DQA1 HLA-DQB1 IFNG
15
Show member pathways
12.83 CD40 CD40LG IL1B MYD88 TLR2 TLR4
16
Show member pathways
12.83 HLA-DQA1 HLA-DQB1 IFNG IL1B IL4 IL6
17
Show member pathways
12.69 IFNG IL10 IL1B IL6 TNF
18
Show member pathways
12.69 HLA-DQA1 HLA-DQB1 IFNG IL10 IL1B IL4
19
Show member pathways
12.61 CCR5 CD40LG IFNG IL10 IL1B IL4
20 12.58 CD40LG CD79A IFNG IL10 IL1B IL4
21 12.55 CD40 HLA-DQA1 HLA-DQB1 IL6 TNF
22
Show member pathways
12.55 IFNG IL1B IL4 IL6 TLR2 TNF
23
Show member pathways
12.53 IFNG IL1B IL6 MYD88 TLR4 TNF
24
Show member pathways
12.52 MYD88 TLR2 TLR4 TLR9 TRAF6
25
Show member pathways
12.52 DHFR IFNG IL1B IL4 IL6 TNF
26
Show member pathways
12.51 CCR5 IFNG IL10 IL4 IL6
27 12.51 CD40 HLA-DQA1 HLA-DQB1 IL6 MYD88 TLR2
28
Show member pathways
12.49 IL6 MYD88 TLR2 TLR4 TLR9 TNF
29
Show member pathways
12.45 CD40 CD40LG HLA-DQA1 HLA-DQB1
30
Show member pathways
12.42 IFNG IL10 IL1B IL4 IL6 TNF
31
Show member pathways
12.42 IL1B IL6 MYD88 TLR2 TNF TRAF6
32
Show member pathways
12.41 IL10 IL1B IL6 MYD88 TLR9 TNF
33 12.38 IFNG IL6 TLR2 TLR4 TLR9 TNF
34
Show member pathways
12.37 CCR5 IL1B MYD88 TLR2 TLR4 TLR9
35
Show member pathways
12.37 CCR5 CD40 CD40LG HLA-DQA1 HLA-DQB1 IFNG
36
Show member pathways
12.3 IFNG IL1B TLR4 TNF
37 12.27 IL10 IL1B IL6 TNF
38 12.24 HLA-DQA1 HLA-DQB1 TLR2 TLR4
39 12.24 IFNG IL1B IL4 IL6 TLR4 TNF
40 12.22 CD79A IFNG IL10 IL4 IL6 TNF
41 12.21 CD40 CD40LG HLA-DQA1 HLA-DQB1
42
Show member pathways
12.21 IFNG IL10 IL1B IL6 TLR2 TLR4
43 12.19 HLA-DQA1 HLA-DQB1 IFNG IL10 IL1B IL6
44
Show member pathways
12.18 CD40 IFNG IL1B IL4 IL6 TLR2
45
Show member pathways
12.17 IFNG IL10 IL1B IL4 IL6
46 12.17 IL10 IL1B IL4 IL6 TNF
47 12.16 IFNG IL1B TNF TRAF6
48
Show member pathways
12.16 CCR5 IFNG IL1B IL4 TRAF6
49
Show member pathways
12.14 IL1B TLR2 TLR4 TLR9
50 12.13 HLA-DQA1 HLA-DQB1 IL1B IL4 IL6 TNF

GO Terms for Toxoplasmosis

Cellular components related to Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CD40 CD40LG IFNG IL10 IL1B IL4
2 integral component of plasma membrane GO:0005887 9.76 CCR5 CD40 CD40LG HLA-DQA1 RHD TLR2
3 cell surface GO:0009986 9.73 CCR5 CD40 CD40LG TLR2 TLR4 TNF
4 external side of plasma membrane GO:0009897 9.43 CCR5 CD40 CD40LG CD79A TLR4 TNF
5 CD40 receptor complex GO:0035631 9.37 CD40 TRAF6
6 endosome membrane GO:0010008 9.1 HLA-DQA1 HLA-DQB1 MYD88 TLR4 TLR9 TRAF6
7 extracellular space GO:0005615 10.01 CD40 CD40LG IFNG IL10 IL1B IL4

Biological processes related to Toxoplasmosis according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Name GO ID Score Top Affiliating Genes
1 response to glucocorticoid GO:0051384 9.99 IL10 IL1B IL6 TNF
2 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.98 TLR4 TLR9 TNF TRAF6
3 positive regulation of smooth muscle cell proliferation GO:0048661 9.97 IL6 MYD88 TNF TRAF6
4 positive regulation of T cell proliferation GO:0042102 9.97 CD40LG IL1B IL4 IL6 TRAF6
5 positive regulation of tumor necrosis factor production GO:0032760 9.96 MYD88 TLR2 TLR4 TLR9
6 positive regulation of nitric oxide biosynthetic process GO:0045429 9.96 IFNG IL1B TLR4 TNF
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.96 IL1B TLR2 TLR4 TLR9 TNF
8 defense response to Gram-negative bacterium GO:0050829 9.95 IL6 TLR4 TLR9
9 interferon-gamma-mediated signaling pathway GO:0060333 9.95 HLA-DQA1 HLA-DQB1 IFNG
10 regulation of inflammatory response GO:0050727 9.95 MYD88 TLR4 TNF
11 toll-like receptor signaling pathway GO:0002224 9.95 MYD88 TLR2 TLR4 TLR9 TRAF6
12 tumor necrosis factor-mediated signaling pathway GO:0033209 9.94 CD40 CD40LG TNF
13 regulation of insulin secretion GO:0050796 9.94 IFNG IL1B TNF
14 positive regulation of JUN kinase activity GO:0043507 9.94 IL1B TLR9 TNF TRAF6
15 positive regulation of B cell proliferation GO:0030890 9.94 CD40 IL4 TLR4 TLR9
16 humoral immune response GO:0006959 9.93 IFNG IL6 TNF
17 JNK cascade GO:0007254 9.93 MYD88 TNF TRAF6
18 interleukin-1-mediated signaling pathway GO:0070498 9.93 IL1B MYD88 TRAF6
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.93 IL1B MYD88 TLR2 TLR4 TNF
20 positive regulation of interferon-gamma production GO:0032729 9.92 IL1B TLR4 TNF
21 B cell proliferation GO:0042100 9.92 CD40 CD40LG CD79A IL10
22 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.92 MYD88 TLR2 TLR4 TLR9 TRAF6
23 protein kinase B signaling GO:0043491 9.91 CD40 IL1B TNF
24 negative regulation of interleukin-6 production GO:0032715 9.91 IL10 TLR4 TLR9 TNF
25 B cell activation GO:0042113 9.9 CD40 CD79A IL4
26 positive regulation of interferon-beta production GO:0032728 9.9 TLR2 TLR4 TLR9
27 inflammatory response GO:0006954 9.9 CCR5 CD40 CD40LG IL10 IL1B IL6
28 negative regulation of neurogenesis GO:0050768 9.89 IL1B IL6 TNF
29 positive regulation of osteoclast differentiation GO:0045672 9.89 IFNG TNF TRAF6
30 positive regulation of interleukin-10 production GO:0032733 9.89 CD40LG TLR2 TLR4 TLR9
31 positive regulation of glial cell proliferation GO:0060252 9.88 IL1B IL6 TNF
32 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.88 IL1B TNF TRAF6
33 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.88 IFNG IL1B TNF
34 toll-like receptor 9 signaling pathway GO:0034162 9.87 MYD88 TLR9 TRAF6
35 negative regulation of growth of symbiont in host GO:0044130 9.87 IL10 MYD88 TNF
36 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.86 IL10 IL1B TNF
37 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.86 TLR2 TLR4 TLR9
38 regulation of cytokine secretion GO:0050707 9.85 TLR2 TLR4 TLR9
39 I-kappaB phosphorylation GO:0007252 9.85 TLR2 TLR4 TLR9
40 positive regulation of interleukin-8 production GO:0032757 9.85 IL1B MYD88 TLR2 TLR4 TLR9 TNF
41 response to molecule of bacterial origin GO:0002237 9.84 IL10 TLR2 TLR9
42 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.83 TLR4 TLR9 TNF
43 positive regulation of chemokine biosynthetic process GO:0045080 9.83 IL1B MYD88 TNF
44 positive regulation of chemokine production GO:0032722 9.83 IL6 TLR2 TLR4 TLR9 TNF
45 positive regulation of MHC class II biosynthetic process GO:0045348 9.81 IL10 IL4 TLR4
46 positive regulation of neuroinflammatory response GO:0150078 9.8 IL1B IL6 TNF
47 positive regulation of interleukin-12 production GO:0032735 9.8 CD40 CD40LG IFNG TLR2 TLR4 TLR9
48 positive regulation of interleukin-6 production GO:0032755 9.8 IL1B IL6 MYD88 TLR2 TLR4 TLR9
49 immune response GO:0006955 9.8 CCR5 CD40LG HLA-DQA1 HLA-DQB1 IFNG IL10
50 negative regulation of interleukin-17 production GO:0032700 9.78 IFNG TLR4

Molecular functions related to Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.4 HLA-DQA1 HLA-DQB1
2 signaling pattern recognition receptor activity GO:0008329 9.37 TLR2 TLR9
3 tumor necrosis factor receptor binding GO:0005164 9.33 CD40LG TNF TRAF6
4 Toll-like receptor binding GO:0035325 9.32 MYD88 TLR2
5 lipopolysaccharide receptor activity GO:0001875 9.26 TLR2 TLR4
6 cytokine activity GO:0005125 9.17 CD40LG IFNG IL10 IL1B IL4 IL6
7 interleukin-1 receptor binding GO:0005149 9.13 IL1B MYD88 TLR9

Sources for Toxoplasmosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....